Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93161 | 0.71 | GABRA1 (0.69) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL18268 | 0.71 | GABRA1 (1.00) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL123887 | 0.71 | GABRA1 (0.88) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL10367327 | 0.70 | ALDH1A1 (0.46) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL30897309 | 0.69 | GABRA1 (0.94) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL201609 | 0.69 | GABRA1 (0.57) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL14007404 | 0.69 | GABRA1 (0.57) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL14973413 | 0.69 | GABRA1 (0.94) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| Hydrochloric Acid SCHEMBL7075850 | 0.69 | GABRA1 (0.94) | GABRA1GABRB2ALDH1A1ALOX15HPGD | |
| SCHEMBL28475477 | 0.69 | GABRA1 (0.94) | GABRA1GABRB2ALDH1A1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101472924-A | KV1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | claimed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | claimed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| CN-1946700-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| CN-101573341-A | Imidazolidinone Kv1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-11-04 | — | — | CN | disclosed |
| CN-101472924-A | KV1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-7402589-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| CN-1946700-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1737830-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | GABRA1 3746/4885GABRB2 3533/4885ALDH1A1 455/4885 |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | GABRA1 658/4885GABRB2 760/4885ALDH1A1 2088/4885 |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | GABRA1 571/4885GABRB2 806/4885ALDH1A1 888/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | GABRA1 658/4885GABRB2 760/4885ALDH1A1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.